Fennec Pharmaceuticals Inc.
NASDAQ:FENCBiotechnology
-$0.12 today
- Market cap
- $470.62M
- Beta
- 1.08
- P/E (TTM)
- -36.3
- EPS (TTM)
- -$0.24
Volume 0.59M
Average 0.26M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
-$12.47M
FY 2025 · Annual
Investing Cash Flow
$0.00
FY 2025 · Annual
Financing Cash Flow
$22.63M
FY 2025 · Annual
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (17.35M) | (23.71M) | (16.05M) | (436K) | (10.27M) |
| Depreciation & Amortization | 16K | 149K | 287K | 959K | 103K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 4.01M | 4.22M | 5.35M | 5.06M | 7.03M |
| Change in Working Capital | (138K) | (509K) | (8.17M) | (7.33M) | (15.09M) |
| Accounts Receivables | 0 | (1.55M) | (7.27M) | (7.87M) | (12.66M) |
| Inventory | 0 | (576K) | (1.58M) | 579K | (1.3M) |
| Accounts Payables | 0 | 0 | 0 | 0 | 1.42M |
| Other Working Capital | (138K) | 1.61M | 683K | (35K) | (2.55M) |
| Other Non-Cash Items | (769K) | 1.8M | 1.43M | 28.73M | 5.76M |
| Operating Cash Flow | (14.22M) | (18.06M) | (17.14M) | 26.98M | (12.47M) |
| Capital Expenditures | 0 | 0 | 0 | 0 | 0 |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | 0 | 0 | 0 | 0 | 0 |
| Debt Repayment | 5M | 20.17M | 5M | (13M) | (19.82M) |
| Common Stock Issued | 33K | 0 | 0 | 0 | 45.01M |
| Common Stock Repurchased | 0 | (194K) | (78K) | (176K) | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (55K) | 753K | 1.72M | (439K) | (2.57M) |
| Financing Cash Flow | 4.98M | 20.73M | 6.64M | (13.62M) | 22.63M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (9.24M) | 2.67M | (10.51M) | 13.37M | 10.15M |
| Free Cash Flow | (14.22M) | (18.06M) | (17.14M) | 26.98M | (12.47M) |
Free Cash Flow
Net Income to FCF bridge
FY2025
Analysis
FY2025 free cash flow is -$12.5M. FCF conversion is 121.4% of net income. Operating cash flow was -$12.5M, with capex of $0. The largest bridge item is Working Capital at -$15.1M.
Competitors
Peer companies in the same sector
Eupraxia Pharmaceuticals Inc.
NASDAQ:EPRX
Market cap
$548.02M
Avalo Therapeutics, Inc.
NASDAQ:AVTX
Market cap
$448.71M
Orchestra BioMed Holdings, Inc.
NASDAQ:OBIO
Market cap
$435.76M
Enanta Pharmaceuticals, Inc.
NASDAQ:ENTA
Market cap
$320.09M
Nautilus Biotechnology, Inc.
NASDAQ:NAUT
Market cap
$295.50M
Prelude Therapeutics Incorporated
NASDAQ:PRLD
Market cap
$275.32M
Cartesian Therapeutics, Inc.
NASDAQ:RNAC
Market cap
$193.69M
Black Diamond Therapeutics, Inc.
NASDAQ:BDTX
Market cap
$84.48M
Caribou Biosciences, Inc.
NASDAQ:CRBU
Market cap
$39.10M
Aardvark Therapeutics, Inc. Common Stock
NASDAQ:AARD
Market cap
$29.11M
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 12, 2026 | |
| 4 | Statement of changes in beneficial ownership | Nov 2, 2026 | |
| 4 | Statement of changes in beneficial ownership | Nov 2, 2026 | |
| 4 | Statement of changes in beneficial ownership | Nov 2, 2026 | |
| 4 | Statement of changes in beneficial ownership | Nov 2, 2026 |
Does FENC generate free cash flow?
Fennec Pharmaceuticals Inc. (FENC) generated -$12.47M of free cash flow in fiscal 2025.
How much operating cash flow does FENC produce?
Operating cash flow was -$12.47M, before capital expenditures of $0.00.
Continue the stock analysis
Jump to another research area for this company.